MPI für molekulare Genetik / Department of Computational Molecular Biology |
|A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling|
|Authors:||Hummel, Michael; Bentink, Stefan; Berger, Hilmar; Klapper, Wolfram; Wessendorf, Swen; Barth, Thomas F.E.; Bernd, Heinz-Wolfram; Cogliatti, Sergio B.; Dierlamm, Judith; Feller, Alfred C.; Hansmann, Martin-Leo; Haralambieva, Eugenia; Harder, Lana; Hasenclever, Dirk; Kühn, Michael; Lenze, Dido; Lichter, Peter; Martin-Subero, Jose Ignacio; Möller, Peter; Müller-Hermelink, Hans-Konrad; Ott, German; Parwaresch, Reza M.; Pott, Christiane; Rosenwald, Andreas; Rosolowski, Maciej; Schwaenen, Carsten; Stürzenhofecker, Benjamin; Szczepanowski, Monika; Trautmann, Heiko; Wacker, Hans-Heinrich; Spang, Rainer; Loeffler, Markus; Trümper, Lorenz; Stein, Harald; Siebert, Reiner|
|Date of Publication (YYYY-MM-DD):||2006-06-08|
|Title of Journal:||The New England Journal of Medicine : NEJM / Publ. by the Massachusetts Medical Society|
|Journal Abbrev.:||N. Engl. J. Med.|
|Issue / Number:||23|
|Copyright:||© 2006 Massachusetts Medical Society. All rights reserved.|
|Review Status:||not specified|
|Abstract / Description:||Background: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas.
Methods: We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization.
Results: We used the molecular signature for Burkitt's lymphoma to identify 44 cases: 11 had the morphologic features of diffuse large-B-cell lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas, and 29 had a classic or atypical Burkitt's morphologic appearance. Also, five did not have a detectable IG-myc Burkitt's translocation, whereas the others contained an IG-myc fusion, mostly in simple karyotypes. Of the 176 lymphomas without the molecular signature for Burkitt's lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases, 21 percent had a chromosomal breakpoint at the myc locus associated with complex chromosomal changes and an unfavorable clinical course.
Conclusions: Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt's lymphoma. In mature aggressive B-cell lymphomas without a gene signature for Burkitt's lymphoma, chromosomal breakpoints at the myc locus were associated with an adverse clinical outcome.
|Comment of the Author/Creator:||Address reprint requests to Dr. Stein at Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Institute of Pathology, Hindenburgdamm 30, D-12200 Berlin Germany, or at Harald.Stein@charite.de.
N Engl J Med. 2006 Sep 7;355(10):1064; author reply 1064-5.
|External Publication Status:||published|
|Version Comment:||Automatic journal name synchronization|
|Communicated by:||Martin Vingron|
|Affiliations:||MPI für molekulare Genetik|
|Sorry, no privileges||
The scope and number of records on eDoc is subject
to the collection policies defined by each institute
- see "info" button in the collection browse view.